1. Home
  2. MAGN vs MYGN Comparison

MAGN vs MYGN Comparison

Compare MAGN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

HOLD

Current Price

$14.51

Market Cap

536.8M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$6.22

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAGN
MYGN
Founded
1864
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.8M
625.5M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
MAGN
MYGN
Price
$14.51
$6.22
Analyst Decision
Buy
Buy
Analyst Count
1
12
Target Price
$18.00
$11.82
AVG Volume (30 Days)
575.2K
923.3K
Earning Date
02-05-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,204,000,000.00
$825,300,000.00
Revenue This Year
$5.74
$0.08
Revenue Next Year
$2.51
$5.28
P/E Ratio
N/A
N/A
Revenue Growth
46.50
0.21
52 Week Low
$7.82
$3.76
52 Week High
$23.19
$15.47

Technical Indicators

Market Signals
Indicator
MAGN
MYGN
Relative Strength Index (RSI) 53.22 38.51
Support Level $14.03 $6.40
Resistance Level $14.77 $7.15
Average True Range (ATR) 0.58 0.30
MACD -0.18 0.02
Stochastic Oscillator 33.90 10.80

Price Performance

Historical Comparison
MAGN
MYGN

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: